Dermapharm Holding SE (0A5J.L)

54,09 +0,14 (+0,26%) In data: 06:18PM BST. Mercato aperto.

Dermapharm Holding SE

Lil-Dagover-Ring 7
Grünwald 82031
Germany
49 89 6 41 86 0
https://ir.dermapharm.de

Settore/i: 
Settore: 
Impiegati a tempo pieno: 3.497

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Hans-Georg Feldmeier	CEO & Chairman of the Management Board	1,05M	N/D	N/D
Mr. Christof Dreibholz	CFO, Chief Compliance Officer & Member of Management Board	617k	N/D	1968
Dr. Andreas Eberhorn	Chief Marketing Officer & Member of Management Board	612k	N/D	1976
Ms. Britta Hamberger	Head of Investor Relations & Corporate Communications	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription healthcare products, herbal extracts, and other pharmaceutical products. It offers healthcare products in the areas of vitamins, minerals, food supplements, dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology. The company also provides medical devices under the bite away and Herpotherm names. Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics. The company was founded in 1991 and is based in Grünwald, Germany. Dermapharm Holding SE operates as a subsidiary of Themis Beteiligungs-AG.

Governance aziendale

L'ISS Governance QualityScore di Dermapharm Holding SE al 1 aprile 2024 è 10. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 10; diritti degli azionisti: 6; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.